Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer
The trial is conducted in Europe. This trial aims for a comparison of the pathology in lymph nodes before and after the effect of recombinant interleukin-21 in patients with stage III melanoma
Cancer|Malignant Melanoma
DRUG: recombinant interleukin-21
Complete pathological response rate in the lymph nodes, After 4 weeks of treatment
Safety, For the duration of the trial|Immunomodulatory effects, For the duration of the trial|Relapse free survival, For up to 4 years after the final visit or until progression of the disease in order to assess the relapse free survival (RFS)
The decision to discontinue the NN028-1801 trial is not due to any safety concerns. The trial was terminated as a result of a strategic decision by the sponsoring company.